Barinthus Biotherapeutics (BRNS) reported second-quarter 2026 financial results and said its proposed combination with Clywedog Therapeutics is progressing toward closing in the second half of 2026.
The company completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in celiac disease. Topline data from the multiple ascending dose portion of the trial are expected in the fourth quarter of 2026.
- Net loss attributable to shareholders was $10.6 million, or $0.26 per share on both basic and diluted bases, for the second quarter of 2026.
- Cash, cash equivalents and restricted cash were $59.6 million as of June 30, 2026, compared with $67.2 million as of March 31, 2026.
- Research and development expenses were $3.9 million, compared with $3.6 million in the first quarter of 2026.
- General and administrative expenses were $7.1 million, compared with $2.5 million in the first quarter of 2026.
- Nasdaq granted the company until Dec. 28, 2026, to regain compliance with the bid price requirement.
- At closing of the Clywedog merger, the combined company is expected to be renamed Clywedog Therapeutics Holdings, Inc. and trade under the ticker CLYD.
$BRNS Hedge Fund Activity
We have seen 4 institutional investors add shares of $BRNS stock to their portfolio, and 2 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RANGELEY CAPITAL, LLC added 75,024 shares (+88.8%) to their portfolio in Q1 2026, for an estimated $42,688
- GTS SECURITIES LLC added 73,210 shares (+inf%) to their portfolio in Q1 2026, for an estimated $41,656
- RENAISSANCE TECHNOLOGIES LLC added 7,900 shares (+5.5%) to their portfolio in Q1 2026, for an estimated $4,495
- UBS GROUP AG removed 3,152 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,793
- MORGAN STANLEY removed 1,196 shares (-35.1%) from their portfolio in Q1 2026, for an estimated $680
- CITADEL ADVISORS LLC added 197 shares (+0.2%) to their portfolio in Q1 2026, for an estimated $112
- GLR PARTNERS, LLC added 0 shares (+0.0%) to their portfolio in Q2 2026, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
